Genmab AS
$ 25.24
3.06%
11 Jun - close price
- Market Cap 15,035,244,000 USD
- Current Price $ 25.24
- High / Low $ 25.39 / 24.80
- Stock P/E 18.69
- Book Value 9.26
- EPS 1.31
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.08 %
- ROE 0.15 %
- 52 Week High 35.43
- 52 Week Low 20.23
About
Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
Analyst Target Price
$36.82
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-17 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-12 | 2024-11-06 | 2024-08-08 | 2024-05-02 | 2024-02-14 | 2023-11-07 | 2023-08-03 |
| Reported EPS | 0.13 | 0.21 | 0.65 | 0.54 | 0.31 | 0.84 | 0.29 | 0.32 | 0.29 | 0.14 | 0.46 | 0.3 |
| Estimated EPS | 0.19 | 0.37 | 0.45 | 0.34 | 0.2 | 0.28 | 0.33 | 0.32 | 0.14 | 0.3 | 0.31 | 0.29 |
| Surprise | -0.06 | -0.16 | 0.2 | 0.2 | 0.11 | 0.56 | -0.04 | 0 | 0.15 | -0.16 | 0.15 | 0.01 |
| Surprise Percentage | -31.5789% | -43.2432% | 44.4444% | 58.8235% | 55% | 200% | -12.1212% | 0% | 107.1429% | -53.3333% | 48.3871% | 3.4483% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.32 |
| Currency | DKK |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GMAB
2026-06-11 17:39:24
Genmab A/S has granted 15,894 restricted stock units (RSUs) and 15,494 warrants to its employees. These awards are part of the company's long-term incentive plans, aiming to align employee interests with shareholder value. Both RSUs and warrants will vest after three years, with specific fair values and exercise prices based on Genmab's share price and the Black-Scholes formula.
2026-06-11 17:39:24
Genmab A/S announced the grant of 15,894 restricted stock units and 15,494 warrants to its employees and subsidiaries on June 11, 2026. These grants are part of the company's compensation programs, with restricted stock units and warrants vesting after three years. The fair value of each RSU is DKK 1,616.50, and the exercise price for each warrant is also DKK 1,616.50.
2026-06-11 16:39:47
Genmab A/S has announced the grant of 15,894 restricted stock units and 15,494 warrants to its employees and subsidiary employees. These grants are cost-free, with the restricted stock units vesting after three years and the warrants vesting after three years and expiring on the seventh anniversary, both subject to specific program conditions. The company's objective is to improve the lives of people with cancer and other serious diseases through innovative antibody medicines.
2026-06-11 16:10:00
Genmab (NASDAQ:GMAB) announced consistent and sustained therapeutic benefits from its epcoritamab plus R2 combination for adults with relapsed or refractory follicular lymphoma. New data from a Phase 3 trial's post-hoc subgroup analysis, presented at EHA 2026, showed lower risks of disease progression or death and significantly higher complete response rates across various high-risk patient subgroups. The safety profile remained manageable, reinforcing its potential as a flexible treatment standard.
2026-06-11 15:39:24
Genmab presented positive results from a post-hoc subgroup analysis of its Phase 3 EPCORE FL-1 trial for relapsed or refractory follicular lymphoma. The combination therapy of epcoritamab with rituximab and lenalidomide showed improved progression-free survival benefits and overall response rates across various patient subgroups, with a manageable safety profile. Genmab, which trades at an undervalued price according to InvestingPro, also reported a 25% increase in Q1 2026 revenue.
2026-06-11 10:45:00
Genmab announced new data from a post-hoc subgroup analysis of the Phase 3 EPCORE FL-1 trial, showing that epcoritamab in combination with rituximab and lenalidomide (R2) delivers consistent and sustained efficacy with a manageable safety profile in relapsed or refractory follicular lymphoma (FL) patients. The data demonstrated significant improvements in progression-free survival (PFS), overall response rates (ORR), and complete response rates (CRR) across various patient subgroups, including those with different FLIPI scores, POD24 status, and patient fitness. These findings reinforce the potential of the combination therapy to transform the treatment paradigm for R/R FL.
